Diabetes Obes Metab: The efficacy of metformin monotherapy in the treatment of type 2 diabetes and previous stage 3 chronic kidney disease

The American Diabetes Association recommends metformin as the initial treatment option for patients with type 2 diabetes (T2D) tolerance
.
The United States reports that 60%-77% of T2D patients receive metformin monotherapy

Results: The average age of the entire cohort was 60.
7 years, 95% of them were men, 21% were African Americans, and 9% had CKD3
.
In the adjusted analysis, compared with non-CKD patients, patients with CKD stage 3 had a higher risk of discontinuing metformin or adding a second hypoglycemic agent (hazard ratio [HR] 1.

Figure Kaplan-Meier analysis of cohort and propensity score matching with and without chronic kidney disease stage 3 (CKD3)
.
A, Kaplan-Meier analysis of metformin discontinuation analysis in patients with and without CKD stage 3

Table Correlation between discontinuation of metformin and the second hypoglycemic agent in patients with stage 3 and non-stage 3 chronic kidney disease in the adjusted analysis

Conclusion: CKD stage 3 and T2D patients have an increased risk of failure of metformin monotherapy

Gosmanov AR, Gemoets DE, Kaminsky LS,et al.